PT Metro Healthcare Indonesia (CARE) Fundamentals 2026 — P/E 411.6x, Revenue Analysis | SniperIQ
PT Metro Healthcare Indonesia (CARE) is a ID-listed Healthcare company in Medical - Care Facilities with a market capitalization of Rp14.03T, trading at Rp422.00 on the JKT. This SniperIQ fundamentals page covers PT Metro Healthcare Indonesia's valuation (P/E 411.6x, P/B 4.6x), profitability (net margin 7.1%), revenue (Rp439.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Metro Healthcare Indonesia's market cap?
PT Metro Healthcare Indonesia (CARE) has a market capitalization of approximately Rp14.03T, trading at Rp422.00 on the JKT. Market cap moves with the live share price.
What is PT Metro Healthcare Indonesia's P/E ratio?
PT Metro Healthcare Indonesia's trailing twelve-month P/E ratio is 411.6x, with a price-to-book (P/B) of 4.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Metro Healthcare Indonesia?
PT Metro Healthcare Indonesia runs a net profit margin of 7.1%, a gross margin of 52.6%, and an operating margin of 22.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Metro Healthcare Indonesia generate?
PT Metro Healthcare Indonesia reported revenue of Rp439.8B for fiscal year 2025, with net income of Rp5.0B and earnings per share (EPS) of 0.15. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Metro Healthcare Indonesia pay a dividend?
PT Metro Healthcare Indonesia does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is PT Metro Healthcare Indonesia financially healthy?
PT Metro Healthcare Indonesia carries a debt-to-equity ratio of 0.35x and a current ratio of 0.84x, with a market beta of -0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Metro Healthcare Indonesia a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Metro Healthcare Indonesia (CARE) the key facts are: market cap Rp14.03T, P/E 411.6x, revenue Rp439.8B, 52-week range 222-965. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Metro Healthcare Indonesia's full fundamentals live
Get PT Metro Healthcare Indonesia's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.